Detail of "156-87-6"

Reference

Quantitative study on the effect of different alkaline agents on the experimental ulcerogenic and analgesic activity of aspirin

Quantitative study on the effect of different alkaline agents on the experimental ulcerogenic and analgesic activity of aspirin. Hertz, F.; Lwoff, J. M.; Boissier, J. R. (Lab. Pharmacol.Some commonly used reagents like 69-46-5 and 34220-70-7 are used in this experiment. II, Ec.-Med., Paris, Fr.). Biol. Gastro-Enterol., 9(3), 193-8 (French) 1976. CODEN: BGENAC. DOCUMENT TYPE: Journal CA Section: 1 (Pharmacodynamics) Aspirin (I) [50-78-2] and its Ca [69-46-5], lysine [34220-70-7], or aminopropanol [62083-12-9] salts had similar ulcerogenic activity in guinea pigs. With I, I lysine, and I aminopropanol (all 400 mg/kg of base), Na2HCO3 decreased ulcerogenic activity without altering analgesic activity in mice. Similar results were obsd. with excess lysine [56-87-1] and aminopropanol [156-87-6] and their resp. I salts. .

Preparation of 1,3,2-oxazaphosphacycloalkane derivatives as matrix metalloproteinase inhibitors

Preparation of 1,3,2-oxazaphosphacycloalkane derivatives as matrix metalloproteinase inhibitors. Sorensen, Morten Dahl; Blaehr, Lars Kristian Albert; Christensen, Mette Knak (Leo Pharmaceutical Products Ltd. A/S (Lovens Kemiske Fabrik Produktionsaktieselskab), Den.). PCT Int. Appl. WO 2002006293 A1 24 Jan 2002, 92 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). (World Intellectual Property Organization). CODEN: PIXXD2. CLASS: ICM: C07F009-6584. ICS: A61K031-675. APPLICATION: WO 2001-DK464 3 Jul 2001. PRIORITY: US 2000-PV219031 18 Jul 2000. DOCUMENT TYPE: Patent CA Section: 29 (Organometallic and Organometalloidal Compounds) Section cross-reference(s): 1, 28, 63 The prepn. of 1,3,2-oxazaphosphacycloalkane derivs. [I; wherein Y = O or S; n = 1, 2, 3 or 4; X = hydroxamic acid, carboxylic acid, phosphonic acid, acetylthiomethyl group or a mercaptomethyl group; R2 = H, (C1-8)alkyl, (C2-6)alkenyl, (C3-8)cycloalkyl, aryl(C0-6)alkyl or heteroaryl(C0-6)alkyl; R1 = optionally substituted alkoxyphenyl, phenoxyphenyl, phenylalkyl, naphthylalkyl, biphenyl, etc.] or a salt, hydrate or solvate thereof is described. Thus, 4-chlorophenylphosphoryl dichloride and N-(3-hydroxypropyl)glycine Et ester underwent a cyclization reaction to give Et 2-(4-chlorophenoxy)-2-oxo-1,3,2-oxazaphosphorinane-3-acetate (I; Y = O; X = CO2Et; R1 = 4-chlorophenoxy; R2 = H; n = 1). The compds. are useful in the treatment of arthritis, rheumatoid arthritis, osteoarthritis, osteopenias, osteoporosis, periodontitis, gingivitis, corneal epidermal or gastric ulceration, skin ageing, tumor metastasis, invasion or growth, multiple sclerosis, psoriasis, proliferative retinopathies, neovascular glaucoma, ocular tumors angiofibroma and hemangioma. Keywords matrix metalloproteinase inhibitor oxazaphosphacycloalkane deriv prepn Index Entries Skin, disease aging, therapeutic agents; prepn. of 1,3,2-oxazaphosphacycloalkane derivs. as matrix metalloproteinase inhibitors Blood vessel, neoplasm angiofibroma, therapeutic agents; prepn. of 1,3,2-oxazaphosphacycloalkane derivs. as matrix metalloproteinase inhibitors Gingiva gingivitis, therapeutic agents; prepn. of 1,3,2-oxazaphosphacycloalkane derivs. as matrix metalloproteinase inhibitors Blood vessel, neoplasm hemangioma, therapeutic agents; prepn. of 1,3,2-oxazaphosphacycloalkane derivs. as matrix metalloproteinase inhibitors Bone, disease osteopenia, therapeutic agents; prepn. of 1,3,2-oxazaphosphacycloalkane derivs. as matrix metalloproteinase inhibitors Periodontium periodontitis, therapeutic agents; prepn. of 1,3,2-oxazaphosphacycloalkane derivs. as matrix metalloproteinase inhibitors Alkylation Cyclization prepn. of 1,3,2-oxazaphosphacycloalkane derivs. as matrix metalloproteinase inhibitors Eye, disease retinopathy, therapeutic agents; prepn. of 1,3,2-oxazaphosphacycloalkane derivs. as matrix metalloproteinase inhibitors Antiglaucoma agents Antitumor agents Antiulcer agents Arthritis Multiple sclerosis Osteoarthritis Osteoporosis Psoriasis Rheumatoid arthritis therapeutic agents; prepn. of 1,3,2-oxazaphosphacycloalkane derivs. as matrix metalloproteinase inhibitors 14221-01-3 51364-51-3 98327-87-8 391641-12-6 391641-13-7 391641-14-8 391641-19-3 391641-20-6 391641-23-9 391641-24-0 391641-25-1 391641-26-2 391641-27-3 391641-28-4 391641-29-5 391641-30-8 391641-31-9 391641-32-0 391641-33-1 391641-34-2 391641-35-3 391641-36-4 391641-37-5 391641-38-6 391641-39-7 391641-41-1 391641-42-2 391641-43-3 391641-44-4 391641-45-5 391641-46-6 391641-47-7 391641-48-8 391641-49-9 391641-50-2 391641-51-3 391641-52-4 391641-53-5 391641-54-6 391641-56-8 391641-15-9 391641-16-0 391641-17-1 391641-18-2 391641-21-7 391641-22-8 391641-40-0 391641-55-7 391641-57-9 391641-58-0 391641-59-1 391641-60-4 391641-61-5 391641-62-6 391641-63-7 391641-64-8 391641-65-9 391641-66-0 391641-67-1 391641-68-2 391641-69-3 391641-70-6 391641-71-7 391641-72-8 391641-73-9 391641-74-0 391641-75-1 391641-76-2 391641-77-3 391641-78-4 391641-79-5 391641-80-8 391641-81-9 391641-82-0 391641-83-1 391641-84-2 391641-85-3 391641-86-4 391641-87-5 391641-88-6 391641-89-7 391641-90-0 391641-91-1 391641-92-2 391641-93-3 391641-94-4 391641-95-5 391641-96-6 391641-97-7 391641-98-8 391641-99-9 391642-00-5 391642-01-6 391642-02-7 391642-03-8 391642-04-9 391642-05-0 391642-06-1 391642-07-2 391642-08-3 391642-09-4 391642-10-7 391642-11-8 391642-12-9 391642-13-0 391642-14-1 391642-15-2 391642-16-3 391642-17-4 391642-18-5 391642-19-6 391642-20-9 391642-21-0 391642-22-1 391642-23-2 391642-24-3 391642-25-4 391642-26-5 391642-27-6 391642-28-7 391642-29-8 391642-30-1 391642-31-2 391642-32-3 391642-33-4 391642-34-5 391642-35-6 391642-36-7 391642-37-8 391642-38-9 391642-39-0 391642-40-3 391642-41-4 391642-42-5 391642-43-6 391642-44-7 391642-45-8 391642-46-9 391642-47-0 391642-48-1 391642-49-2 391642-50-5 391642-51-6 62-53-3, reactions 98-80-6 98-88-4 105-36-2 122-01-0 156-87-6 764-11-4 772-79-2 824-72-6 2508-29-4 3497-00-5 4648-58-2 13325-10-5 33666-90-9 34909-18-7 37632-18-1 55004-22-3 68453-82-7 77918-50-4 77918-51-5 98273-58-6 118481-84-8 161518-66-7 391642-52-7 391642-53-8 391642-54-9 391642-55-0 391642-56-1 391642-57-2 391642-58-3 391642-59-4 391642-60-7 391642-61-8 391642-62-9 391642-63-0 391642-64-1 391642-65-2 391642-66-3 391642-67-4 391642-68-5 391642-69-6 391642-70-9 104125-18-0 391640-17-8 391640-18-9 391640-19-0 391640-20-3 391640-21-4 391640-22-5 391640-23-6 391640-24-7 391640-25-8 391640-26-9 391640-27-0 391640-28-1 391640-29-2 391640-30-5 391640-31-6 391640-32-7 391640-33-8 391640-34-9 391640-35-0 391640-36-1 391640-37-2 391640-38-3 391640-39-4 391640-40-7 391640-41-8 391640-42-9 391640-43-0 391640-44-1 391640-45-2 391640-46-3 391640-47-4 391640-48-5 391640-49-6 391640-50-9 391640-51-0 391640-52-1 391640-53-2 391640-54-3 391640-55-4 391640-56-5 391640-57-6 391640-58-7 391640-59-8 391640-60-1 391640-61-2 391640-62-3 391640-63-4 391640-64-5 391640-65-6 391640-66-7 391640-67-8 391640-68-9 391640-69-0 391640-70-3 391640-71-4 391640-72-5 391640-73-6 391640-74-7 391640-75-8 391640-76-9 391640-77-0 391640-78-1 391640-79-2 391640-80-5 391640-81-6 391640-82-7 391640-83-8 391640-84-9 391640-85-0 391640-86-1 391640-87-2 391640-88-3 391640-89-4 391640-90-7 391640-91-8 391640-92-9 391640-93-0 391640-94-1 391640-95-2 391640-96-3 391640-97-4 391640-98-5 391640-99-6 391641-00-2 391641-01-3 391641-02-4 391641-03-5 391641-04-6 391641-05-7 391641-06-8 391641-07-9 391641-08-0 391641-09-1 391641-10-4 391641-11-5 prepn. of 1,3,2-oxazaphosphacycloalkane derivs. as matrix metalloproteinase inhibitors